Rianne C J Beckers1, Doenja M J Lambregts2, Max J Lahaye2, Sheng-Xiang Rao3, Kelly Kleinen4, Cecile Grootscholten5, Geerard L Beets6, Regina G H Beets-Tan7, Monique Maas8. 1. GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiology, Maastricht University Medical Center, The Netherlands; Department of Surgery, Maastricht University Medical Center, The Netherlands. 2. Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. 4. Department of Medical Oncology, Viecuri Hospital, Venlo, The Netherlands. 5. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 7. GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 8. Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: moniquemaas@live.nl.
Abstract
BACKGROUND: The assessment of colorectal liver metastases (CRLM) after treatment with chemotherapy is challenging due to morphological and/or functional change without changes in size. The aim of this review was to assess the value of FDG-PET, FDG-PET-CT, CT and MRI in predicting response to chemotherapy in CRLM. METHODS: A systematic review was undertaken based on PRISMA statement. PubMed and Embase were searched up to October 2016 for studies on the accuracy of PET, PET-CT, CT and MRI in predicting RECIST or metabolic response to chemotherapy and/or survival in patients with CRLM. Articles evaluating the assessment of response after chemotherapy were excluded. RESULTS: Sixteen studies met the inclusion criteria and were included for further analysis. Study results were available for 6 studies for FDG-PET(-CT), 6 studies for CT and 9 studies for MRI. Generally, features predicting RECIST or metabolic response often predicted shorter survival. The ADC (apparent diffusion coefficient, on MRI) seems to be the most promising predictor of response and survival. In CT-related studies, few attenuation-related parameters and texture features show promising results. In FDG-PET(-CT), findings were ambiguous. CONCLUSION: Radiological data on the prediction of response to chemotherapy for CRLM is relatively sparse and heterogeneous. Despite that, a promising parameter might be ADC. Second, there seems to be a seemingly counterintuitive correlation between parameters that predict a good response and also predict poor survival.
BACKGROUND: The assessment of colorectal liver metastases (CRLM) after treatment with chemotherapy is challenging due to morphological and/or functional change without changes in size. The aim of this review was to assess the value of FDG-PET, FDG-PET-CT, CT and MRI in predicting response to chemotherapy in CRLM. METHODS: A systematic review was undertaken based on PRISMA statement. PubMed and Embase were searched up to October 2016 for studies on the accuracy of PET, PET-CT, CT and MRI in predicting RECIST or metabolic response to chemotherapy and/or survival in patients with CRLM. Articles evaluating the assessment of response after chemotherapy were excluded. RESULTS: Sixteen studies met the inclusion criteria and were included for further analysis. Study results were available for 6 studies for FDG-PET(-CT), 6 studies for CT and 9 studies for MRI. Generally, features predicting RECIST or metabolic response often predicted shorter survival. The ADC (apparent diffusion coefficient, on MRI) seems to be the most promising predictor of response and survival. In CT-related studies, few attenuation-related parameters and texture features show promising results. In FDG-PET(-CT), findings were ambiguous. CONCLUSION: Radiological data on the prediction of response to chemotherapy for CRLM is relatively sparse and heterogeneous. Despite that, a promising parameter might be ADC. Second, there seems to be a seemingly counterintuitive correlation between parameters that predict a good response and also predict poor survival.
Authors: Marco Ravanelli; Giorgio Maria Agazzi; Elena Tononcelli; Elisa Roca; Paolo Cabassa; Gianluca Baiocchi; Alfredo Berruti; Roberto Maroldi; Davide Farina Journal: Radiol Med Date: 2019-06-06 Impact factor: 3.469
Authors: Francesco De Cobelli; Marco Calandri; Angelo Della Corte; Roberta Sirovich; Carlo Gazzera; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Daniele Maiettini; Giovanni Mauri; Nicola Camisassi; Stephanie Steidler; Francesca Ratti; Simone Gusmini; Monica Ronzoni; Luca Aldrighetti; Bruno C Odisio; Patrizia Racca; Paolo Fonio; Andrea Veltri; Franco Orsi Journal: Eur Radiol Date: 2022-01-29 Impact factor: 7.034
Authors: Brett S Walker; Thomas L Sutton; Luai Zarour; John G Hunter; Stephanie G Wood; V Liana Tsikitis; Daniel O Herzig; Charles D Lopez; Emerson Y Chen; Skye C Mayo; Melissa H Wong Journal: Ann Surg Oncol Date: 2021-08-07 Impact factor: 5.344